Home > Insider Trading > Filing (0001562180-24-000326)

Filing Details

Accession Number:: 0001562180-24-000326
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-01-08 06:03:20
Reporting Period:: 2024-01-03

Accepted Time:: 2024-01-08 06:03:20
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1560241	G1 Therapeutics Inc.	GTHX	Pharmaceutical Preparations (2834)	263648180

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1706853	Rajesh Malik	700 Park Offices Drive, Suite 200 Research Triangle Park NC 27709	Chief Medical Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-01-03	37,300	$0.00	173,678	No	4	A	Direct
Common Stock	Disposition	2024-01-03	758	$3.12	172,920	No	4	S	Direct
Common Stock	Disposition	2024-01-03	2,261	$3.12	170,659	No	4	S	Direct
Common Stock	Disposition	2024-01-04	721	$2.94	169,938	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options (Right to Buy)	Acquisiton	2024-01-03	74,500	$0.00	74,500	$2.97

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
74,500		2034-01-03	No	4	A	Direct

Footnotes

Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2025 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
The shares underlying this option vest as to 25% of the shares on January 3, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
Each RSU represents a contingent right to receive one share of Issuer common stock.
Represents (i) 71,853 shares of common stock; (ii) 4,125 RSUs from award granted on January 4, 2021; (iii) 7,500 RSUs from award granted on January 3, 2022; (iv) 17,900 RSUs from award granted on January 3, 2023; (v) 35,000 RSUs from award granted on May 10, 2023; and (vi) 37,300 RSUs from award granted on January 3, 2024.
The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person.
The price represents the weighted average price with a low of $3.08 and a high of $3.16. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents (i) 72,595 shares of common stock; (ii) 4,125 RSUs from award granted on January 4, 2021; (iii) 6,000 RSUs from award granted on January 3, 2022; (iv) 17,900 RSUs from award granted on January 3, 2023; (v) 35,000 RSUs from award granted on May 10, 2023; and (vi) 37,300 RSUs from award granted on January 3, 2024.
Represents (i) 74,809 shares of common stock; (ii) 4,125 RSUs from award granted on January 4, 2021; (iii) 6,000 RSUs from award granted on January 3, 2022; (iv) 13,425 RSUs from award granted on January 3, 2023; (v) 35,000 RSUs from award granted on May 10, 2023; and (vi) 37,300 RSUs from award granted on January 3, 2024.
The price represents the weighted average price with a low of $2.89 and a high of $3.00. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents (i) 75,463 shares of common stock; (ii) 2,750 RSUs from award granted on January 4, 2021; (iii) 6,000 RSUs from award granted on January 3, 2022; (iii) 13,425 RSUs from award granted on January 3, 2023; (iv) 35,000 RSUs from award granted on May 10, 2023; and (v) 37,300 RSUs from award granted on January 3, 2024.